Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven
Randomized controlled trials (RCTs) are the gold standard for testing the safety and efficacy of new drugs and biologicals. The US Food and Drug Administration (FDA) has proactively improved the trial designs to make them scientifically rational while avoiding unnecessary human exposure. Several new...
Saved in:
| Main Author: | Sarfaraz K. Niazi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/11/1424 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost of care associated with utilization of telehealth in clinical trials
by: Emily Gleason, et al.
Published: (2024-12-01) -
Study on knowledge, practices, and attitudes toward decentralized clinical trials among the clinical trial practitioners in China
by: Yuanyuan Shi, et al.
Published: (2025-04-01) -
Conducting clinical trials with self-collection of pharmacokinetic samples: Experience from an exploratory, phase 1, open-label trial of centanafadine SR in healthy individuals
by: Chelsea Ye, et al.
Published: (2025-02-01) -
Clinical trial budgeting approaches in Switzerland—a meta-research study
by: Alexandra Griessbach, et al.
Published: (2025-05-01) -
Signals for change: A regional examination of rural clinical trial participant perspectives on values, health behaviors, and motivations for enrollment and retention in remote settings
by: Elizabeth A. Johnson, et al.
Published: (2025-01-01)